PSDV - pSivida Limited Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PSDV - pSivida Limited

PSDV 1.220

+14.0%

Mar 29 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: John McCarthy	10/7/2010 5:14:39 PM
	Read Replies (1) of 421

Buy REGN Ahead Of VEGF Trap-Eye Data In December PiperJaffray says it is a buyer of Regeneron Pharmaceuticals (NASDAQ: REGN) ahead of pivotal VEGF Trap-Eye data in Age-related Macular Degeneration (AMD) in December. If approved, we believe VEGF Trap-Eye could be a game changer for Regeneron pushing the company to profitability in 2012. Regeneron retains U.S. rights where there are >200,000 new cases of AMD each year. PiperJaffray conservatively forecasts sales of $710 million by 2015 with only 25% penetration. If VEGF Trap-Eye proves superior to Lucentis on either metric, we could see more rapid uptake and increased peak penetration. Regeneron is partnered with Bayer overseas and receives 50% of the profits providing further upside to its revenue forecast and price target. Including $165 million from Astellas, Regeneron holds proforma cash of $545 million and no debt. Trading at a market cap of $2.1 billion and an enterprise value of $1.6 billion, Piper sees shares of REGN as attractive. PiperJaffray reiterates its Overweight rating on REGN and a $37 price target. benzinga.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next